ZBIO · Zenas BioPharma, Inc.
$33.04
-0.73 (-2.16%)
At close · Aug 26
Market Cap
$2.15B
Shares
65.18M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10M
+100%
FY2025
Net Income
-$377.74M
-140.6%
FY2025
Operating Margin
-3830.57%
-552.8pp
FY2025
Diluted EPS
-$8.44
+29%
FY2025
Operating Cash Flow
-$172.33M
-44%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $10M | $5M | $50M | |
| $213.47M | $168.06M | $139.14M | $60.03M | |
| $61.43M | $53.32M | $29.75M | $17.11M | |
| $476.57M | $393.06M | $168.89M | $87.15M | |
| -$475.57M | -$383.06M | -$163.89M | -$37.15M | |
| — | -3830.57% | -3277.76% | -74.29% | |
| — | $7.33M | — | — | |
| — | $12.15M | $7.97M | — | |
| -$8.59M | $5.24M | $7.33M | $324K | |
| -$484.16M | -$377.82M | -$156.56M | -$36.82M | |
| — | -$79K | $429K | $301K | |
| -$484.38M | -$377.74M | -$156.99M | -$37.12M | |
| — | -3777.37% | -3139.76% | -74.25% | |
| -$485.43M | -$378M | -$156.83M | -$37.05M | |
| USD/shares | — | -$8.44 | -$11.89 | -$24.25 |
| USD/shares | — | -$8.44 | -$11.89 | -$24.25 |
| shares | — | 44.73M | 13.2M | 1.53M |
| shares | — | 44.73M | 13.2M | 1.53M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.14×
EV/EBIT
—
Peer median 17.16×
P/E (TTM)
—
Peer median 17.79×
Peer medians compare against the 258 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $10,000,000 | $5,000,000 | $50,000,000 |
Key facts
CIK
1953926
CUSIP
98937L105
13F (30d)
137 filings
134 filers
Visit website
Investor relations